Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine
2022 ASCO Annual Meeting
Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumors. The presence of a deficiency of MGMT, the drug-resistance gene, was associated with greater odds of an objective response (Abstract 4004).
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
This study is a randomized phase two study through ECOG-ACRIN called E2211. And it's a study that examines capecitabine and temozolomide versus temozolomide alone in patients with advanced pancreatic neuroendocrine tumors. And this study was conceived at a time when we had few available agents for pancreatic NETs and there's a subset of patients with pancreatic neuroendocrine tumors who need an objective response, tumor shrinkage. And a number of our available agents don't yield responses. They yield prolonged stability. And so this was an opportunity to really test cytotoxic chemotherapy in this patient population. Until this time we had streptozocin, which is an IV alkylating chemotherapy for this patient population. It was FDA approved in the 1980s. And since then we haven't had many other cytotoxic chemotherapies available for this group of patients.
Temozolomide is an oral alkylating agent, and it has advantages over streptozocin in the sense that it is orally bioavailable, it crosses the blood brain barrier, and it has a better side effect profile. Temozolomide was selected as the comparator arm, compared to cape-tem, or capecitabine temozolomide, as we wanted both arms to examine temozolomide prospectively. This was a design that randomized 144 patients one to one, so there were 72 patients on each arm. The maximum treatment duration was 13 cycles, or about a year. And the primary endpoint was progression-free survival by local review and secondary endpoints included response rate, overall survival, and a safety assessment. And we had correlative analyses on MGMT, methylguanine methyltransferase, which is a DNA-repair enzyme that were reported as part of this study. And so, in terms of the endpoints, the interim analysis, which was reported at ASCO 2018, showed that there was a median progression-free survival benefit of capecitabine and temozolomide of 22 versus 14 months for temozolomide alone. And this updated analysis shows that there is no benefit or difference in overall survival between the arms, however, no statistical difference, I should say. However, there is a clinically relevant, significant difference of about five months between the two arms. The other really key part of this presentation is the MGMT correlative analysis. That indicates MGMT deficiency as defined by immunohistochemistry low or promoter methylation positive. Both of those at MGMT deficient are associated with increased response. So this study, because both arms contain temozolomide, is not a study that will help us to determine if MGMT is predictive of response, but we do see that it's associated with increased responses. The other interesting thing that we learned is that MGMT by IHC is more common, whereas MGMT by promoter methylation is not as common. And, of the patients that received both tests, it appears as if there are likely other reasons for MGMT down regulation outside of methylation. So, in summary, this is one of the first prospective randomized studies to demonstrate a prolonged median progression-free survival of 22 months. And there was no statistically significant difference in overall survival, but there was a clinically meaningful difference of about five months. And MGMT deficiency is associated with an increased response. The takeaways clinically are that capecitabine temozolomide really should be considered a standard of care and included in guidelines for patients with advanced pancreatic NETs. Routine use of MGMT testing is not recommended. However, for patients who really need objective responses, we can consider using MGMT testing. There are some follow up studies. So there are two that are in progress. One is a clinical trial. They're both actually through the national clinical trial network. One is a clinical trial looking at the adjuvant use of capecitabine temozolomide following surgery for patients with high risk pancreatic NETs. And it's looking at four months of capecitabine temozolomide versus placebo. And another is a clinical trial examining lutetium dotatate radioligand therapy versus capecitabine temozolomide in advanced pancreatic NETs.
Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in this disease. The analysis showed that high-dose ifosfamide is more effective in prolonging survival than topotecan plus cyclophosphamide (Abstract LBA2).
Bradley J. Monk, MD, of the University of Arizona College of Medicine and Creighton University School of Medicine, discusses phase III findings from the ATHENA–MONO (GOG-3020/ENGOT-ov45) trial. It showed that rucaparib as first-line maintenance treatment, following first-line platinum-based chemotherapy, improved progression-free survival in patients with ovarian cancer, irrespective of homologous recombination deficiency status (Abstract LBA5500).
Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses long-term phase II findings of a trial evaluating crenolanib plus chemotherapy in newly diagnosed adults with FLT3-mutant acute myeloid leukemia. The study showed a composite complete remission rate of 86%. With a median follow-up of 45 months, median overall survival has not been reached. A phase III trial is ongoing (Abstract 7007).
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).
Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, and Matthew Krebs, PhD, of The University of Manchester and The Christie NHS Foundation Trust, discuss results from the CHRYSALIS study. The trial showed that the bispecific antibody amivantamab-vmjw demonstrated antitumor activity, even after prior treatment, in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation (Abstract 9008).